Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5b

2 Nov 2015 14:08

RNS Number : 2375E
GoldmanSachs International
02 November 2015
 

Ap27

 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

(GS) GOLDMAN SACHS INTERNATIONAL

Company dealt in

PFIZER INC

Class of relevant security to which the dealings being disclosed relate (Note 1)

USD ordinary & GDR

Date of dealing

30 October 2015

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

2,490,638 (0.04)

678,606 (0.01)

(2) Derivatives (other than options)

0 (0.00)

 0 (0.00)

(3) Options and agreements to purchase/sell

0 (0.00)

 0 (0.00)

Total

2,490,638 (0.04)

678,606 (0.01)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Ap28

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

100

33.9650 USD

Sale

100

131.7100 BRL

Purchase (Borrow New)

24,628

N/A

Sale (Borrow Full Return)

24,628

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Purchase (Borrow New)

34,428

N/A

Sale (Borrow Full Return)

34,428

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Purchase (Borrow New)

2,035,239

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Sale (Borrow Full Return)

1,809,103

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Purchase (Borrow New)

17,428

N/A

Sale (Borrow Full Return)

17,428

N/A

Purchase (Borrow New)

34,428

N/A

Sale (Borrow Full Return)

34,428

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

Purchase (Borrow New)

28,228

N/A

Sale (Borrow Full Return)

28,228

N/A

Purchase (Borrow New)

12,428

N/A

Sale (Borrow Full Return)

12,428

N/A

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(Note 4)

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

Ap29

 

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities

under any option referred to on this form or relating to the voting rights or future acquisition

or disposal of any relevant securities to which any derivative referred to on this form is referenced.

If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)  YES/NO

 

 

Date of disclosure

02 November 2015

Contact name

Aadithya Rao and Yiannis Bardis

Telephone number

+44(20) 7051 9046 / +44(20) 7774 7107

Name of offeree/offeror with which connected

Pfizer Inc

Nature of connection (Note 9)

Advisor to Offeror

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEEALFAEEKSFFF
Date   Source Headline
16th May 201411:29 amRNSForm 8.5 (EPT/RI)
16th May 201411:27 amRNSForm 8 (DD) - [Pfizer Inc]
16th May 201411:18 amRNSForm 8.3 - Pfizer Inc
16th May 201411:13 amRNSForm 8.5 (EPT/RI)
16th May 201411:12 amRNSForm 8.5 (EPT/NON-RI)
16th May 201411:00 amRNSRule 2.10 Announcement
16th May 201410:31 amRNSForm 8.3 - Pfizer Inc
16th May 20149:18 amRNSRule 2.10 Announcement
16th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
15th May 20145:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20145:50 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20145:16 pmRNSForm 8 (DD) - [Pfizer Inc]
15th May 20145:14 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
15th May 20143:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:50 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:33 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:32 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
15th May 20143:28 pmBUSForm 8.3 - Pfizer Inc
15th May 20143:26 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
15th May 20143:22 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:10 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:02 pmBUSForm 8.3 - Pfizer Inc.
15th May 20142:50 pmRNSForm 8.3 - [PFIZER INC]
15th May 20142:42 pmBUSForm 8.3 - Pfizer Inc
15th May 20142:29 pmRNSForm 8.3 - [Pfizer Inc]
15th May 20141:55 pmRNSForm 8.5 (EPT/RI) Pfizer Inc. Amendment
15th May 20141:36 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:34 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20141:26 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:24 pmRNSForm 8 (DD) - Pfizer Inc.
15th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
15th May 201412:57 pmBUSForm 8.3 - Pfizer Inc.
15th May 201412:39 pmRNSForm 8.3 - [AstraZeneca Plc]
15th May 201412:22 pmRNSForm 8.3 - [Pfizer Inc]
15th May 201412:15 pmRNSForm 8.5 (EPT/NON-RI)
15th May 201412:10 pmRNSForm 8.5 (EPT/RI)
15th May 201412:09 pmBUSForm 8.3 - Pfizer Inc
15th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
15th May 201411:34 amRNSForm 8 (DD) - [Pfizer Inc]
15th May 201411:32 amRNSForm 8.5 (EPT/RI)
15th May 201411:27 amRNSForm 8.5 (EPT/RI) Pfizer Inc
15th May 201411:04 amRNSForm 8.3 - Pfizer Inc
15th May 201411:00 amRNSForm 8.5 (EPT/RI) - Pfizer
15th May 201411:00 amRNSRule 2.10 Announcement
15th May 20149:39 amRNSRule 2.10 Announcement
14th May 20144:48 pmRNSForm 8.3 - Replacement - Pfizer Inc
14th May 20143:31 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc.
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:23 pmRNSForm 8.3 - AstraZeneca Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.